Q5113 HCPCS code: Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg
Q5113 is the HCPCS Level II code for injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg. In 2023 Medicare paid an average of $23.24 per service for Q5113 across 7,174 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 120 per day on outpatient hospital claims. Medicare volume rose 43% from 2022 to 2023 (5,027 to 7,174 services). In 2023, about 28 clinicians billed Medicare for Q5113 for 23 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2019-07-01 |
| Last action effective | 2023-10-01 |
Who bills Q5113 (2023)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 28 |
| Medicare beneficiaries | 23 |
| States with claims | 1 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for Q5113, 2022–2023
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 5,027 | 22 | $48.40 | $38.51 |
| 2023 | 7,174 | 23 | $29.18 | $23.24 |
States with the most Q5113 services (2023)
| State | Services | Avg. paid |
|---|---|---|
| Wisconsin | 6,364 | $22.96 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 120 | Clinical: Society Comment |
| practitioner claims | 120 | Clinical: Society Comment |
What changed for Q5113
- 2019-07-01: Q5113 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q5113?
Q5113 is the HCPCS Level II code for injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg. Short descriptor: "Inj herzuma 10 mg".
How much does Medicare pay for Q5113?
In 2023, the average Medicare payment was $23.24 per service (average allowed $29.18).
Does Medicare cover Q5113?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of Q5113 can be billed per day?
120 on outpatient hospital claims; 120 on practitioner claims (NCCI medically unlikely edits).
Related Q51 codes
- Q5100 — Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 — Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102 — Injection, infliximab, biosimilar, 10 mg
- Q5103 — Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 — Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108 — Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110 — Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 — Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q5113
- Watch Q5113 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5113
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.